NeoRAS wild-type in metastatic colorectal cancer: Myth or truth? —Case series and review of the literature

Upfront KRAS and NRAS gene testing ( ‘RAS’) is the standard of care for metastatic colorectal cancer (mCRC), to guide first-line treatment. The presence of RAS mutation (MT) is a negative predictor for the efficacy of anti-EGFR antibodies and the use of cetuximab and panitumumab is restricted to RAS wild-type (WT) mCRC. Conversion from RAS WT to RAS MT mCRC after treatment with anti-EGFR antibodies is a known and well-described acquired resistance mechanism. The by far less frequent ‘NeoRAS wild-type’ phenomenon (reversion from RAS MT to RAS WT) has recently drawn attention.

Source: European Journal of Cancer - June 18, 2021 Category: Cancer & Oncology Authors: Hiroki Osumi, Loredana Vecchione, Ulrich Keilholz, Claudia Vollbrecht, Annabel H.S. Alig, Jobst C. von Einem, Arndt Stahler, Jana K. Striefler, Annika Kurreck, Andreas Kind, Dominik P. Modest, Sebastian Stintzing, Ivan Jelas Tags: Original Research Source Type: research